7 in 10 US adults would still test for COVID if they suspected infection, survey suggests

News brief

Testing for COVID-19 — *Jernej Furman / Flickr cc*

Seven in 10 respondents to a 2024 US survey said they would still reach for a home COVID-19 test if they thought they were infected, UMass Chan Medical School researchers report in JAMA Network Open.

The team used the Ipsos KnowledgePanel to ask 2009 adults whether they would test and, if not, the reasons for not testing, from October 31 to November 7, 2024. The average participant age was 51.5 years, 51.2% were women, 60.7% were White, 18.0% were Hispanic, and 12.1% were Black.

The investigators noted that COVID-19 remains a threat, with the Centers for Disease Control and Prevention (CDC) estimating 28,000 to 46,000 related US deaths and 230,000 to 390,000 hospitalizations from October 2024 to April 2025.

"Early identification of infection enables prompt care and steps to reduce spread," they wrote. "Timely initiation of oral antiviral medications is associated with lower hospitalizations, deaths, and long-COVID incidence among adults at high risk."

Older, healthy respondents more likely to test

Most participants (70.0%) said they would test if they suspected a COVID-19 infection. Factors tied to intent to test were age older than 60 years, excellent health status, trust in the healthcare system, reliance on data to make health decisions, previous completion of a home test, and Black, Hispanic, or mixed race.

Test hesitancy may delay oral antiviral initiation and could result in missed opportunities to limit transmission.

The proportion endorsing each reason for not testing were perceived lack of a reason to test (53.6%), a belief that a positive test result wouldn't be useful (30.1%), lack of trust in tests (20.7%), forgetting that testing is an option (19.4%), preference of not knowing the results (9.1%), lack of awareness of where to procure a test (5.8%), inability to pay for testing (4.9%), and other reasons (8.3%).

The authors called for raising awareness of the value of testing. "Nearly one-third of US adults would not or might not test for suspected COVID-19, largely because they do not see value in testing," they wrote. "Test hesitancy may delay oral antiviral initiation and could result in missed opportunities to limit transmission."

Catch-up needed after non-COVID vaccination plunges in first 2 pandemic years

News brief

Mary Van Beusekom, MS

Parent with daughter and doctor — *Drazen Zigic / iStock*

Non–COVID-19 vaccination dropped in the first 2 years of the pandemic, raising concerns about potential outbreaks of avoidable diseases, the resurgence of previously controlled diseases, and widening health disparities for people with weakened immune systems, according to a study published in PLOS One.

Researchers from the University of Kentucky and Augusta University used clinical records from the American Board of Family Medicine’s PRIME Registry from March 2019 through March 2022 to calculate monthly primary-care visit and vaccination rates among US children and adults.

"The COVID-19 pandemic caused substantial burdens for patients and our healthcare delivery system," they wrote. "Many patients delayed seeking care for essential medical needs, and providers struggled to deliver services."

Implications for clinical practice, policy

Relative to before the pandemic, the number of vaccinated participants fell 9.6% among children and 4.2% in adults in pandemic year 1, dropping 19.4% and 14.2%, respectively, the next year. While primary-care visit rates rebounded somewhat, vaccination rates didn't return to baseline. And except for a few months, vaccination rates stayed lower than visit rates.

Enhancing standardized reporting tools, reminders, and patient outreach systems could help clinicians more effectively identify and reach under-vaccinated individuals.

Women, rural residents, and those living in socially deprived areas were the least likely to be vaccinated, and this gap widened throughout the second pandemic year. "These findings underscore the need for targeted outreach and support for rural populations, where structural barriers and limited access to care may compound pandemic-related disruptions," the authors wrote.

They said that the study has implications for clinical practice and public health. "Catch-up vaccination efforts are urgently needed, particularly in rural and socioeconomically disadvantaged communities," they wrote. "Strategies could include mobile clinics, school-based drives, and reminder systems."

At the policy level, the researchers urged stronger support to help primary care clinics provide essential preventive services during public health emergencies. "Enhancing standardized reporting tools, reminders, and patient outreach systems could help clinicians more effectively identify and reach under-vaccinated individuals," they concluded.

Partnership aims to foster development of drug for non-TB mycobacteria

News brief

Jim Wappes

Mycobacteria — Dept of Engineering, University of Cambridge / Flickr cc

BioVersys AG announced today a research and exclusive license option agreement with Japanese pharmaceutical company Shionogi & Co to jointly develop its novel preclinical ansamycin platform for developing treatments of non-tuberculous mycobacteria (NTM), BioVersys said in a news release.

Shionogi will pay BioVersys 5 million Swiss francs ($6.3 million US) up front for developing BV500, BioVersys's NTM drug candidate and, upon exercise of the license option, regulatory and sales milestones of up to 479 million Swiss francs ($605 million) as well as royalties on future sales.

'Significant unmet medical needs'

Marc Gitzinger, PhD, chief executive officer and co-founder of BioVersys, said, "We are excited to work with our colleagues at Shionogi to advance the development of our NTM asset expeditiously towards patients in need. This collaboration reduces research and development risk for BioVersys while preserving financial discipline. It also expands the reach of our pipeline and ensures the expedited development of our drug candidates.”

Nawaz Khan, PhD, head of research at BioVersys, added, "BV500 has the potential to become a best in class therapeutic for NTM infections. We are proud that the program attracted such a strong partner."

BV500 has the potential to become a best in class therapeutic for NTM infections.

John Keller, PhD, senior vice president at Shionogi, said, "This collaboration reflects our commitment to advancing innovative treatments for infectious diseases with significant unmet medical needs."